鼻咽癌3种分割放疗方式所致口腔粘膜损伤的比较  

Comparison of oral mucosal injury in three types of fraction radiotherapy of nasopharyngeal carcinoma

作　　者：谭永红[1] 郑成位[1] 

机构地区：[1]第三军医大学附属大坪医院野战外科研究所放疗科，重庆 400042

出　　处：《第三军医大学学报》2000年第9期882-884,共3页Journal of Third Military Medical University

摘　　要：目的　比较鼻咽癌常规分割、全程超分割、后程加速超分割 3种放射治疗方式所致的放射性口腔粘膜损伤。方法　 72例首程放疗的鼻咽癌患者随机分为常规分割组 (CFR)、全程超分割组 (FHR)、后程加速超分割组 (LAHR)各 2 4例。鼻咽部总剂量 :CFR组 70～ 72Gy 7～ 7.5周 ,每天照射 1次 ,每次 2Gy ;FHR组80 .5～ 82 .8Gy 7～ 7.5周 ,每天照射 2次 ,间隔 6h以上 ,每次 1.15Gy ;LAHR组先常规分割照射 3 8～ 40Gy 3 .5～ 4周 ,再加速超分割照射 3 3～ 3 6Gy 2～ 2 .5周 ,每天 2次 ,间隔 6h以上 ,每次 1.5Gy。结果　Ridit分析提示急性放射性口腔粘膜损伤FHR组明显重于CFR组 ;LAHR组与CFR组比较无差异。结论　后程加速超分割放疗不增加口腔粘膜放射性损伤。Objective To compare the acute radiation oral mucosal injuries resulting from conventional fraction radiotherapy, full course hyperfractionated radiotherapy and late course accelerated hyperfractionated radiotherapy for nasopharyngeal carcinoma. Methods Seventy two patients with nasopharyngeal carcinoma, were randomized into three groups and treated with conventional fraction radiation (CFR) (24 cases), full course hyperfractionated radiation (FHR) (24 cases) and late course accelerated hyperfractionated radiation (LAHR) (24 cases) respectively. Patients in CFR group received 2 Gy/F, 5 Fraction/week with the total dose of 70-72 Gy/7-7.5 weeks, those in FHR group received 2 Fraction/a day with 6 hour interval, 1.15 Gy/F with total dose of 80.5-82.8 Gy/7-7.5 weeks, and those in LAHR group received conventional fraction radiotherapy of 38-40 Gy/3.5-4 weeks firstly, and then received the accelerated hyperfractionated radiotherapy for 2-2.5 weeks (1.5 Gy/F, 2F/day with 6 hour interval), with the total dose of 33～36 Gy. Results Ridit's analysis indicated that acute radiation oral mucosal injury was more severe in FHR group than in CFR and there was no difference of the oral mucosa injury between the LAHR and CFR group. Conclusion The late course accelerated hyperfraction radiotherapy dose not intensify acute radiation oral mucosal injury.

关 键 词：鼻咽癌 超分割放疗 副作用 口腔粘膜损伤 

分 类 号：R739.630.6[医药卫生—肿瘤] R781.5[医药卫生—临床医学]